Table 3.

Annual signal detection metrics for TIN associated with statin use (2017–2024).

Year	TIN cases (n)	Reported ADEs with statins	ROR (95% CI)	PRR	EBGM	IC
2017	5	7,646	0.80 (0.33–1.92)	0.8	0.81	−0.30
2018	9	9,639	0.41 (0.21–0.80)	0.41	0.43	−1.22
2019	2	12,089	0.07 (0.017–0.27)	0.07	0.08	−3.55
2020	12	10,088	1.13 (0.64–2.00)	1.13	1.13	0.17
2021	17	7,656	2.08 (1.29–3.35)	2.08	2.01	1.00
2022	16	6,976	2.89 (1.76–4.74)	2.89	2.71	1.44
2023	17	7,754	2.40 (1.49–3.88)	2.4	2.3	1.20
2024	42	8,503	5.77 (4.24–7.85)	5.75	5.32	2.41